Publications

UCAN Health Economics Publications

Quantifying hospital-associated costs, and accompanying travel costs and productivity losses, before and after withdrawing TNF-α inhibitors in juvenile idiopathic arthritis. Florax AA, Doeleman MJH, De Roock S, Van Der Linden N, Schatorjé E, Currie G, et al. Rheumatology. 2023 Dec 20;kead688
Managing juvenile idiopathic arthritis within the context of their life: What we learnt from children and youth living with juvenile idiopathic arthritis and their parents. Currie GR*, Kennedy BL*, Benseler SM, Yeung RSM, Swart JF, Vastert SJ, Wulffraat NM, Kip MMA, MacKean G, Marshall DA. Musculoskeletal Care. 2023 Dec;21(4):1248–60.
What matters most to pediatric rheumatologists in deciding whether to discontinue biologics in a child with juvenile idiopathic arthritis? A best-worst scaling survey. Currie GR, Groothuis-Oudshoorn CGM, Twilt M, Kip MMA, IJzerman MJ, Benseler SM, Swart JF, Vastert SJ, Wulffraat NM, Yeung R, Marshall DA. Clin Rheumatol. 2023 Aug;42(8):2173–80.
Withdrawing biologics in non-systemic JIA: what matters to pediatric rheumatologists? Van Til JA, Kip MMA, Schatorjé EJH, Currie G, Twilt M, Benseler SM, Swart JF, Vastert SJ, Wulfraat N, Yeung RSM, Groothius-Oudshoorn CGM, Warta S, *Marshall DM, *Ijzerman MJ and on behalf of the UCAN CAN-DU, UCAN CURE consortia. Pediatr Rheumatol. 2023 Jul 11;21(1):69.
Evaluating key performance indicators of the process of care in juvenile idiopathic arthritis. Cooper SM, Currie GR, Kromm S, Twilt M, Marshall DA. Pediatr Rheumatol. 2023 Apr 21;21(1):37.
Pharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands: a real-world data analysis. Kip MMA, De Roock S, Currie G, Marshall DA, Grazziotin LR, Twilt M, Rae S M Yeung, Benseler SM, Vastert SJ, Wulffraat N, Swart JF, IJzerman MJ. Rheumatology. 2023 Feb 23;62(SI2):SI170–80.
Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study. Grazziotin LR, Currie G, Twilt M, Ijzerman MJ, Kip MMA, Koffijberg H, Benseler SM, Swart JF, Vastert SJ, Wulffraat NM, Yeung RSM, Marshall DA. Pediatr Rheumatol. 2022 Dec;20(1):25.
Factors associated with care- and health-related quality of life of caregivers of children with juvenile idiopathic arthritis. Grazziotin LR, Currie G, Twilt M, IJzerman MJ, Kip MMA, Koffijberg H, Bonsel G, Benseler SM, Swart JF, Vastert SJ, Wulffraat NM, Yeung RSM, Armbrust W, Merlijn van den Berg J, Marshall DA. Pediatr Rheumatol. 2022 Dec;20(1):51.
Costs of Hospital-associated Care for Patients With Juvenile Idiopathic Arthritis in the Dutch Health Care System. Kip MMA, De Roock S, Van Den Berg I, Currie G, Marshall DA, Grazziotin LR, Twilt M, Yeung RSM, Benseler SM, Vastert SJ, Wulffraat N, Swart JF, IJzerman MJ. Arthritis Care & Research. 2022 Oct;74(10):1585–92.
Perspectives of Pediatric Rheumatologists on Initiating and Tapering Biologics in Patients with Juvenile Idiopathic Arthritis: A Formative Qualitative Study. Currie GR, Pham T, Twilt M, IJzerman MJ, Hull PM, Kip MMA, Benseler S, Hazlewood GS, Yeung R, Wulffraat N, Swart JF, Vastert SJ, Marshall DA. Patient. 2022 Sep;15(5):599–609.
Costs of medication use among patients with juvenile idiopathic arthritis in the Dutch healthcare system. Kip MMA, De Roock S, Currie G, Marshall DA, Grazziotin LR, Twilt M, Yeung RSM, Benseler SM, Schreijer MA, Vastert SJ, Wulffraat N, van Royen-Kerkhof A, Swart JF, IJzerman MJ. Expert Review of Pharmacoeconomics & Outcomes Research. 2021 Sep 3;21(5):975–84.
Evaluation of Real-World Healthcare Resource Utilization and Associated Costs in Children with Juvenile Idiopathic Arthritis: A Canadian Retrospective Cohort Study. Grazziotin LR, Currie G, Twilt M, Ijzerman MJ, Kip MMA, Koffijberg H, Benseler SM, Swart JF, Bastert SJ, Wulffraat NM, Yeung RSM, Johnson N, Luca NJ, Miettunen PM, Schmeling H, Marshall DA. Rheumatol Ther. 2021 Sep;8(3):1303–22.
A Canadian evaluation framework for quality improvement in childhood arthritis: key performance indicators of the process of care. Barber CEH, Twilt M, Pham T, Currie GR, Benseler S, Yeung RSM, Batthish M, Blanchette N, Guzman J, Lang B, LeBlanc C, Levy DM, O’Brin C, Schmeling H, Soon G, Spiegel L, Whitney K, Marshall DA. Arthritis Res Ther. 2020 Dec;22(1):53.
Health State Utility Values in Juvenile Idiopathic Arthritis: What is the Evidence? Grazziotin LR, Currie G, Kip MMA, IJzerman MJ, Twilt M, Lee R, Marshall DM. PharmacoEconomics. 2020 Sep;38(9):913–26.
Seeking the state of the art in standardized measurement of health care resource use and costs in juvenile idiopathic arthritis: a scoping review. Kip MMA, Currie G, Marshall DA, Grazziotin Lago L, Twilt M, Vastert SJ, Swart JF, Wulffraat N, Yeung RSM, Benseler SM, Ijzerman M. Pediatr Rheumatol. 2019 Dec;17(1):20.